<DOC>
	<DOCNO>NCT00343941</DOCNO>
	<brief_summary>This pilot study design determine dose schedule Tucaresol administer HIV-1 infected subject HAART ( highly active antiretroviral therapy ) viral suppression without occurrence significant adverse event result significant change cell mediate immunity .</brief_summary>
	<brief_title>Tucaresol As Add-On To HAART ( Highly Active Antiretroviral Therapy ) In Chronic HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Currently license triple combination therapy , define two nucleoside analogue ( 2 NRTI ) ( exclude Abacavir ) protease inhibitor ( PI ) ( include boost PI regimen ) non nucleoside reverse transcriptase inhibitor ( NNRTI ) . Must treatment least 3 month prior study without plan alter therapy next 3 month . Plasma HIV1 RNA ( ribonucleic acid ) &lt; 50 copies/mL screening document history continuous suppression define : last two reading &lt; 50 copies/mL period least 3 month prior screen . Documented CD4+ lymphocyte cell count =350 cells/ml screen least one reading =350 cells/mL precede 3 month CD4 nadir &gt; 200 cells/ml . HBsAg ( human hepatitis B Virus surface antigen ) HCVAb ( human hepatitis C Virus antibody ) negative . History hyperimmune allergic reaction drug treatment within 3 month prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>Tucaresol</keyword>
	<keyword>Viral suppression</keyword>
</DOC>